Nutritional Genomics Institute

I see this constantly in practice: a patient comes in with classic Lyme symptoms-fatigue, joint pain, brain fog-but their serology came back negative. And they're told they don't have Lyme. End of story.

Except it's not. Here are the five reasons why a single antibody panel fails:

1. Antibody Lag Time - Early Lyme infection may not trigger detectable antibodies for 2-4 weeks. Test too early, and you miss it entirely. Serial testing at strategic intervals catches seroconversion.

2. Evolving Immune Response - The immune system's antibody profile changes as Borrelia burgdorferi progresses and adapts. A static snapshot at week 3 tells you nothing about week 12 or month 6. You need multiple data points.

3. Asymptomatic Progression - Many people carry active infection without obvious symptoms at the moment of testing. Genomic markers (like Borrelia DNA or host inflammatory signatures) reveal active replication that serology misses entirely.

4. Treatment Response Detection - Antibodies persist long after successful treatment. If you're retesting to confirm eradication, serology is useless. Genomic markers and serial immune panels show actual clearance.

5. Genomic Marker Sensitivity - Standard serology has a 10-20% false-negative rate in early infection. Adding PCR, next-gen sequencing, and host biomarkers dramatically improves sensitivity and specificity.

This is why at GenMedx we don't rely on one test. We layer serial serology with genomic markers, immune profiling, and symptom tracking. It's the only way to close the diagnostic gap and actually catch what single-draw antibody panels leave hidden.

If you're managing Lyme patients, what's your current testing protocol? Drop a comment-I'd love to hear how you're handling this in your practice.

Two women.
Same hormone labs.
Same HRT dose.

One thrives.
One gets anxiety, insomnia, weight gain, breast tenderness, and brain fog.

Most practitioners call this “trial and error.”

We call it bad medicine.

Why?

Because labs tell us **WHAT** your hormone levels are.
Your genes tell us **HOW** your body processes them.

That’s the difference between standard HRT and **Precision HRT**.

Three genes matter more than most providers realize:

**CYP1B1**
Controls the 4-OH pathway (reactive estrogen metabolites).

**Fast CYP1B1:** estrogen clears too aggressively → symptomatic despite “normal” dosing
**Slow CYP1B1:** reactive metabolites build up → higher oxidative stress + potential cancer risk

**Support:** microdosing, transdermal delivery, DIM, antioxidants

**CYP1A1**
Regulates the 2-OH pathway (often the more favorable pathway).

**Slow CYP1A1:** better estrogen retention
**Upregulated CYP1A1:** faster estrogen turnover; if downstream detox is weak, risk rises

**Support:** optimize dose + route, avoid overdriving detox

**COMT**
Clears estrogen metabolites, dopamine, and adrenaline.

**COMT Met/Met (slow):**
Higher estrogen sensitivity
More anxiety
More overstimulation

**Support:** lower doses, magnesium, methylation support, reduce catecholamine load

**COMT Val/Val (fast):**
Faster clearance of estrogen + neurotransmitters
More prone to low dopamine symptoms: fatigue, flat mood, low drive

**Support:** stable hormone delivery, avoid overmethylation, too much magnesium may worsen fatigue

Same hormones.
Different genetics.
Completely different protocol.

Your HRT plan should never be guesswork.

Your genes already know the answer.

**Does your provider?**

Learn more about our GenMedx Programs!